Full-Time

Associate Director

Patient Navigator Services

Posted on 11/15/2024

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$195k - $215kAnnually

Senior

Villanova, PA, USA + 1 more

More locations: San Bruno, CA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary

You match the following Cytokinetics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s Degree required
  • At least 5 years experience in rare disease and/or patient support solutions (required)
  • Experience launching products in biopharma industry (required)
  • Prior experience managing outsourced service provider(s)
  • Experience in specialty pharmacy and REMS design, launch execution and daily monitoring
  • Demonstrated experience of direct leadership of a functional team and/or significant experience leading in-direct teams; including exemplary coaching skills
  • Demonstrated leadership skills with ability to drive decision-making and results, ability to meet both the needs of the business and the customer
  • Demonstrated problem solving skills with ability to identify, implement and monitor solution outcomes
  • Excellent collaboration and interpersonal skills; able to foster cooperation and lead cross-functionally
  • Excellent written and oral communication skills to effectively convey complex information to stakeholders
  • Effective facilitation skills; appropriately speaks up to raise issues; keeps team and management fully apprised of initiative status and issues
  • Demonstrated accomplishments in delivering objectives of new projects/initiatives
Responsibilities
  • Act as the single point of contact for the Patient/Provider Navigator and REMS team; establish governance for effective oversight of the service provider.
  • Develop and implement solutions to improve the patient medication treatment experience for prescribed products with primary focus on helping patients navigate access and adherence to the product.
  • Collaborate with cross-functional teams such as Trade & Distribution, Sales & Marketing, Data & Insights and Medical Affairs to develop and implement the integrated Patient and Provider medication treatment journey.
  • Actively manage navigator and REMS performance against set objectives and SLAs and resolve operational issues that may hinder a seamless patient experience and delay a patient from starting therapy.
  • Partner with Reporting & Insights function for the standard reporting and insight generation required to monitor performance and drive continuous improvement.
  • Support training of the team and ensure compliance with all applicable policies and procedures.
  • Ensure all relevant policies, SOPs, and work instructions are developed and maintained.
  • Responsible for financial management of the function, including budget, contract management, resources and ensuring productivity against impact is delivered.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent investments indicate strong interest in muscle activators and inhibitors.
  • Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
  • Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

What critics are saying

  • Increased competition could impact market share and profitability.
  • Potential delays in clinical trials could hinder drug commercialization.
  • Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and aficamten.
  • Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-5%

2 year growth

-2%
Stock Titan
Jan 6th, 2025
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.

BioSpace
Dec 20th, 2024
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Cytokinetics announces Sanofi acquired rights to develop and commercialize Aficamten in Greater China.

MarketBeat
Nov 26th, 2024
Intech Investment Management LLC Invests $1.73 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)

Intech Investment Management LLC invests $1.73 million in Cytokinetics, Incorporated (NASDAQ:CYTK).

MediaPost
Oct 11th, 2024
Cytokinetics Educates Docs On Non-Physical Ordeals Of Cardio Condition

Setting the stage for its first consumer product after 25 years as a biopharma development company, Cytokinetics has launched "HCM Beyond the Heart," an awareness campaign educating cardiologists and other healthcare professionals (HCP) about the personal burdens caused by hypertrophic cardiomyopathy (HCM), a leading cause of sudden cardiac death.

Business Directory 88
Aug 21st, 2024
Armistice Capital Performance: A Closer Look at Healthcare Investment Strategies

Armistice Capital has invested in Cytokinetics Incorporated, a late-stage biopharmaceutical organization investigating treatments for impaired muscle function-related cardiovascular and neuromuscular diseases.

Stock Titan
May 23rd, 2024
Cytokinetics Announces Pricing of Public Offering of Common Stock | $CYTK Stock News

Cytokinetics prices public offering at $51/share, expected to raise $500M. Offering closes May 28, 2024, with J.P. Morgan, Goldman Sachs, Morgan Stanley as managers.

Seeking Alpha
May 22nd, 2024
Cytokinetics to get up to $575M in funding from Royalty Pharma

Under the deal, Cytokinetics will receive $50M for the commercial launch

Stock Titan
May 22nd, 2024
Cytokinetics Secures $575M Funding from Royalty Pharma

Royalty Pharma and Cytokinetics have expanded their strategic funding collaboration, totaling up to $575 million, to support the commercial launch of aficamten and advance Cytokinetics' cardiovascular R&D pipeline. The deal includes immediate $250 million funding, with additional options tied to clinical and regulatory milestones. Key elements include $50 million for commercial launch, $100 million for a Phase 3 trial, $50 million for a Phase 2 trial, and a $50 million equity purchase by Royalty Pharma.

GlobeNewswire
May 22nd, 2024
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Development funding: Cytokinetics will receive $100 million in upfront capital to fund a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure and reduced ejection fraction.

MarketBeat
May 20th, 2024
Bridger Management LLC Makes New $1.88 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)

Bridger Management LLC makes new $1.88 million investment in Cytokinetics, Incorporated (NASDAQ:CYTK).

INACTIVE